Tarceva for Non-small cell lung cancer with EGFR mutations
Quick answer: Tarceva is used for Non-small cell lung cancer with EGFR mutations as part of a egfr tyrosine kinase inhibitor treatment regimen. Reversibly inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR), blocking downstream tumor signaling The specific dosing for Non-small cell lung cancer with EGFR mutations is determined by your prescriber based on individual factors.
Why is Tarceva used for Non-small cell lung cancer with EGFR mutations?
Tarceva belongs to the EGFR tyrosine kinase inhibitor class. Reversibly inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR), blocking downstream tumor signaling This action makes it useful for treating or managing Non-small cell lung cancer with EGFR mutations in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Tarceva is the right choice for a specific patient depends on the type and severity of Non-small cell lung cancer with EGFR mutations, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Non-small cell lung cancer with EGFR mutations
Common adult dosing range: 100-150 mg once daily. The actual dose for Non-small cell lung cancer with EGFR mutations depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Tarceva medicine page.
What to expect
Tarceva treatment for Non-small cell lung cancer with EGFR mutations typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Non-small cell lung cancer with EGFR mutations
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Tarceva is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all EGFR tyrosine kinase inhibitor for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Tarceva
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Tarceva full prescribing information · All EGFR tyrosine kinase inhibitor alternatives
Frequently asked questions
How effective is Tarceva for Non-small cell lung cancer with EGFR mutations?
Effectiveness varies by individual response, dose, and severity. Tarceva is one of several treatment options for Non-small cell lung cancer with EGFR mutations, supported by clinical evidence within the egfr tyrosine kinase inhibitor class. Discuss expected response with your prescriber.
How long do I need to take Tarceva for Non-small cell lung cancer with EGFR mutations?
Treatment duration depends on the nature of Non-small cell lung cancer with EGFR mutations — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Tarceva when used for Non-small cell lung cancer with EGFR mutations?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Tarceva for Non-small cell lung cancer with EGFR mutations?
Yes. Multiple medicines and non-drug options exist for Non-small cell lung cancer with EGFR mutations. Alternatives within the egfr tyrosine kinase inhibitor class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.